Robert Smith is a Rheumatology/Immunology physician. ClinicalTrials.gov lists 15 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
4301 W 57th St Ste 160
Sioux Falls, SD 571082288
Telephone
605-332-7000Registry record last updated 15 Jun 2016.
Clinical trials
- Guided Internet-based Interventions in Primary Care Effectiveness-implementation Randomized Controlled Trial
Sponsor: Norwegian Institute of Public Health
- Epicardial Mitral Touch System for Mitral Insufficiency
Sponsor: Mitre Medical Corp.
- Edwards PASCAL CLASP IID/IIF Pivotal Clinical Trial
Sponsor: Edwards Lifesciences
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
13 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Genentech USA, Inc.Program year20257 payments
- ARS Pharmaceuticals Operations, Inc.Program year20251 payment
- AstraZeneca Pharmaceuticals LPProgram year20253 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Respiratory
95.3%Corticosteroid34.8%Fluticasone Propionate29%Arnuity Ellipta24%Dulera17%Breo Ellipta14%Budesonide-Formoterol Fumarate9%Qvar Redihaler8%Part D<11 patientsHistamine-1 Receptor Antagonist27.4%Azelastine Hcl77%Levocetirizine Dihydrochloride23%Part D≥46 patients+ 5 more classes in this area
Metabolism & gastrointestinal
2.5%Corticosteroid2.5%Prednisone100%Part D<11 patientsDermatology
2.2%Interleukin-4 Receptor alpha Antagonist2.2%Dupixent Syringe100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
David J. Hunter
The University of Sydney
Aziz Sheikh
Universiti Malaysia Terengganu
Nima Hafezi‐Nejad
The University of Sydney
Gelin Xu
Second Affiliated Hospital of Nanjing Medical University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”